Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy

被引：12

作者：

Baj, Andreina ^{[1
,2
]}

Novazzi, Federica ^{[1
]}

Ferrante, Francesca D. ^{[1
]}

Genoni, Angelo ^{[2
]}

Cassani, Gianluca ^{[1
]}

Prestia, Martina ^{[1
]}

Colombo, Alberto ^{[1
]}

Capuano, Riccardo ^{[1
]}

Zago, Christian ^{[1
]}

Pasciuta, Renee ^{[1
]}

Tamborini, Antonio ^{[1
]}

Rossi, Agostino ^{[1
]}

Tettamanzi, Elena ^{[3
]}

Catanoso, Giuseppe ^{[3
]}

Focosi, Daniele ^{[2
,4
]}

Maffioli, Lorenzo ^{[5
]}

Maggi, Fabrizio ^{[1
,2
]}

机构：

[1] ASST Sette Laghi, Lab Microbiol, Varese, Italy

[2] Univ Insubria, Dept Med & Surg, Varese, Italy

[3] ATS Insubria, Varese, Italy

[4] Pisa Univ Hosp, North Western Tuscany Blood Bank, Pisa, Italy

[5] ASST Sette Laghi, Varese, Italy

来源：

JOURNAL OF MEDICAL VIROLOGY | 2021年 / 93卷 / 12期

关键词：

D O I：

10.1002/jmv.27235

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：6460 / 6461

页数：2

共 5 条

[1]

Acevedo ML., 2021, INFECTIVITY IMMUNE E, DOI DOI 10.1101/2021.06.28.21259673

[2] Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines [J].

Focosi, Daniele ;

Maggi, Fabrizio .

REVIEWS IN MEDICAL VIROLOGY, 2021, 31 (06)

[3] Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape [J].

Koenig, Paul-Albert ;

Das, Hrishikesh ;

Liu, Hejun ;

Kuemmerer, Beate M. ;

Gohr, Florian N. ;

Jenster, Lea-Marie ;

Schiffelers, Lisa D. J. ;

Tesfamariam, Yonas M. ;

Uchima, Miki ;

Wuerth, Jennifer D. ;

Gatterdam, Karl ;

Ruetalo, Natalia ;

Christensen, Maria H. ;

Fandrey, Caroline, I ;

Normann, Sabine ;

Toedtmann, Jan M. P. ;

Pritzl, Steffen ;

Hanke, Leo ;

Boos, Jannik ;

Yuan, Meng ;

Zhu, Xueyong ;

Schmid-Burgk, Jonathan L. ;

Kato, Hiroki ;

Schindler, Michael ;

Wilson, Ian A. ;

Geyer, Matthias ;

Ludwig, Kerstin U. ;

Hallberg, B. Martin ;

Wu, Nicholas C. ;

Schmidt, Florian, I .

SCIENCE, 2021, 371 (6530) :691-+

[4]

Starr Tyler N, 2021, bioRxiv, DOI [10.1016/j.xcrm.2021.100255, 10.1101/2021.02.17.431683]

[5]

Tada T., SARS COV 2 LAMBDA VA, DOI 10.1101/2021.07.02.450959

← 1 →